Appointment of Independent Non-Executive Director

AI SummaryClose X

Coiled Therapeutics plc has appointed Craig A. Tooman as an Independent Non-Executive Director, effective June 25, 2026, bringing extensive experience in the pharmaceutical and biotechnology sectors, including raising nearly US$9 billion in capital and leading significant M&A transactions. Mr. Tooman's background includes serving as CEO of Silence Therapeutics and leading the US$250 million merger of Aratana Therapeutics with Elanco, as well as the US$1.1 billion acquisition of ILEX Oncology by Genzyme Corporation. In connection with his appointment, Mr. Tooman has been granted options over 4,000,000 ordinary shares at an exercise price of 10 pence each, with vesting over six and twelve months.

Disclaimer*

UK 100

Latest directors dealings